Renalytix PLC
LSE:RENX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (207.3), the stock would be worth GBX37.32 (1 973% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 10 | GBX1.8 |
0%
|
| 3-Year Average | 207.3 | GBX37.32 |
+1 973%
|
| 5-Year Average | 428.4 | GBX77.14 |
+4 185%
|
| Industry Average | 0 | GBX0 |
-100%
|
| Country Average | 0 | GBX0 |
-100%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Renalytix PLC
LSE:RENX
|
7.9m GBP | 10 | -0.5 | |
| JP |
|
Medical Data Vision Co Ltd
TSE:3902
|
37.9T JPY | 13.6 | 227.5 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 6.7 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
25.9B USD | 8 | 28.5 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14.1B AUD | 55.8 | 60 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 5.1 | 20.8 | |
| SE |
|
Sectra AB
STO:SECT B
|
49.7B SEK | 35.5 | 91.8 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.8B USD | 8.1 | 42.2 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD | 6.5 | 18.7 | |
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
261.1B INR | 8.8 | 40.3 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | 17.3 | -328 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 664.3 |
Other Multiples
Renalytix PLC
Glance View
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
